Oracle Goddess writes "Buying DRMed content, then having that content stop working later, is fair, writes Steven Metalitz, the lawyer who represents the MPAA, RIAA in a letter to the top legal advisor at the Copyright Office. 'We reject the view that copyright owners and their licensees are required to provide consumers with perpetual access to creative works.' In other words, if it stops working, too bad. Not surprisingly, Metalitz also strongly opposes any exemption that would allow users to legally strip DRM from content if a store goes dark and takes down its authentication servers."

Al writes "A team of researchers at the Georgia Institute for Technology say they have developed a way to catch spam before it even arrives on the mail server. Instead of bothering to analyze the contents of a spam message, their software, called SNARE (Spatio-temporal Network-level Automatic Reputation Engine), examines key aspects of individual packets of data to determine whether it might be spam. The team, led by assistant professor Nick Feamster, analyzed 2.5 million emails collected by McAfee in order to determine the key packet characteristics of spam. These include the geodesic proximity of end mail servers and the number of ports open on the sending machine. The approach catches spam 70 percent of the time, with a 0.3 false positive rate. Of course, revealing these characteristics could also allow spammers to fake their packets to avoid filtering."

A 62-year-old man visiting his relatives in the US was held for four hours by immigration officials after they could not detect his fingerprints because of a cancer drug he was taking. The man was prescribed capecitabine, a drug used to treat cancers in the head, neck, breast, and stomach. Some of the drug's side-effects include chronic inflammation of the palms or soles of the feet, which can cause the skin to peel or bleed. "This can give rise to eradication of fingerprints with time," explained Tan Eng Huat, senior consultant in the medical oncology department at Singapore's National Cancer Center. "Theoretically, if you stop the drug, it will grow back, but details are scanty. No one knows the frequency of this occurrence among patients taking this drug and nobody knows how long a person must be on this drug before the loss of fingerprints," he added.